Ann: Research Report on NuSep , page-11

bear in mind that Nusep will dilute to 50% of PrIme which is probably a blessing given there will be other motivated shareholders with skin in the game. our membranes are valuable IP and retained by NSP. no-one will acquire shares in PrIme without extreme confidence in the technology and the ability to make sales. shenanigans aside, directors and shareholders will be looking for a genuine resurrection in the perception of this company, which may take a little bit more time to materialise...